BR112018000206A2 - indicador terapêutico atômico - Google Patents
indicador terapêutico atômicoInfo
- Publication number
- BR112018000206A2 BR112018000206A2 BR112018000206A BR112018000206A BR112018000206A2 BR 112018000206 A2 BR112018000206 A2 BR 112018000206A2 BR 112018000206 A BR112018000206 A BR 112018000206A BR 112018000206 A BR112018000206 A BR 112018000206A BR 112018000206 A2 BR112018000206 A2 BR 112018000206A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- ati
- relates
- determining
- hmrs
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
- G01N27/64—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode using wave or particle radiation to ionise a gas, e.g. in an ionisation chamber
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T17/00—Three dimensional [3D] modelling, e.g. data description of 3D objects
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/103—Treatment planning systems
- A61N5/1039—Treatment planning systems using functional images, e.g. PET or MRI
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Computer Graphics (AREA)
- Geometry (AREA)
Abstract
a presente invenção refere-se à geração de um indicador terapêutico atômico (ati) para uma amostra em teste pela quantificação de manganês, em voxels, de uma região tridimensional (3d) da amostra, em que a região 3d é definida topograficamente pelas coordenadas x'xy'xz. o ati é utilizado para avaliar a responsividade à radioterapia, ou seja, a sensibilidade ou resistência ao tratamento com radiação de um câncer, ou seja, um tumor/uma neoplasia. em uma modalidade preferida, a presente invenção refere-se a um método para geração do ati, avaliando a responsividade à radioterapia de um tumor/uma neoplasia com base no ati e, de acordo com a avaliação, tratar ou não o tumor com radiação. a presente invenção também se refere a um método para determinar se é provável a recorrência de um câncer após o tratamento com radiação, compreendendo quantificar o nível de manganês em voxels de uma região 3d de uma amostra em teste do câncer e determinar a frequência de regiões de elevada metalômica (hmrs) no câncer, em que frequência alta de hmrs é indicativa de que o câncer provavelmente recorrerá e frequência baixa de hmrs é indicativa de que o câncer provavelmente não recorrerá, e a métodos associados de tratamento. a invenção refere-se ainda um método para determinar a responsividade à radioterapia de um melanoma, em que o método compreende determinar o nível de melanina em uma amostra em teste do melanoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015902706A AU2015902706A0 (en) | 2015-07-09 | Atomic therapeutic indicator | |
| PCT/AU2016/050603 WO2017004684A1 (en) | 2015-07-09 | 2016-07-11 | Atomic therapeutic indicator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018000206A2 true BR112018000206A2 (pt) | 2018-09-04 |
Family
ID=57684750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018000206A BR112018000206A2 (pt) | 2015-07-09 | 2016-07-11 | indicador terapêutico atômico |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10254284B2 (pt) |
| EP (1) | EP3320521B1 (pt) |
| JP (1) | JP6603802B2 (pt) |
| KR (1) | KR102046265B1 (pt) |
| CN (1) | CN108027982A (pt) |
| BR (1) | BR112018000206A2 (pt) |
| CA (1) | CA2991246C (pt) |
| ES (1) | ES2781876T3 (pt) |
| MX (1) | MX2018000104A (pt) |
| WO (1) | WO2017004684A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016222299B1 (en) | 2015-07-09 | 2016-11-03 | Atomic Oncology Pty Ltd | Atomic Therapeutic Indicator |
| CN110399649B (zh) * | 2019-07-03 | 2023-05-30 | 中国石油天然气集团有限公司 | 一种基于成岩指示元素的变质岩量化识别方法 |
| US11415582B2 (en) | 2019-10-24 | 2022-08-16 | King Fahd University Of Petroleum And Minerals | Method for detecting and treating colon cancer by measuring heavy metal concentrations |
| CN111241086B (zh) * | 2020-01-17 | 2021-08-31 | 甘肃省卫生健康统计信息中心(西北人口信息中心) | 一种基于医疗大数据的数据质量改进方法及系统 |
| CN111624191A (zh) * | 2020-03-02 | 2020-09-04 | 北京理工大学 | 一种离在体通用的脑肿瘤活检和边界确定装置 |
| JP2022131579A (ja) | 2021-02-26 | 2022-09-07 | キオクシア株式会社 | 分析装置および分析方法 |
| CN115372604B (zh) * | 2022-07-07 | 2023-03-28 | 山东第一医科大学附属省立医院(山东省立医院) | 一种用于预测肿瘤患者免疫治疗疗效的标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008007A (en) | 1997-01-31 | 1999-12-28 | Oncotech, Inc. | Radiation resistance assay for predicting treatment response and clinical outcome |
| CA2665100C (en) | 2006-10-02 | 2017-01-03 | Cancercare Manitoba | Methods of detecting and monitoring cancer using 3d analysis of centromeres |
| CN102576060B (zh) * | 2009-10-06 | 2016-05-11 | 皇家飞利浦电子股份有限公司 | 辐射剂量的回顾式计算和改进的处置规划 |
| JPWO2011155168A1 (ja) * | 2010-06-07 | 2013-08-01 | パナソニック株式会社 | 組織悪性腫瘍検出方法、組織悪性腫瘍検出装置 |
| EP2633063A4 (en) * | 2010-10-28 | 2015-11-04 | Univ Virginia Commonwealth | CANCER IMAGING USING THERAPY: THE THERANOSTIC |
| AU2014321355B2 (en) | 2013-09-20 | 2019-10-10 | The Regents Of The University Of Michigan | Compositions and methods for the analysis of radiosensitivity |
| WO2015047226A1 (en) | 2013-09-24 | 2015-04-02 | Halliburton Energy Services, Inc. | Evaluation of downhole electric components by monitoring umbilical health and operation |
| AU2016222299B1 (en) | 2015-07-09 | 2016-11-03 | Atomic Oncology Pty Ltd | Atomic Therapeutic Indicator |
-
2016
- 2016-07-11 CN CN201680052282.7A patent/CN108027982A/zh active Pending
- 2016-07-11 US US15/517,112 patent/US10254284B2/en active Active
- 2016-07-11 MX MX2018000104A patent/MX2018000104A/es active IP Right Grant
- 2016-07-11 WO PCT/AU2016/050603 patent/WO2017004684A1/en active Application Filing
- 2016-07-11 KR KR1020187003969A patent/KR102046265B1/ko active IP Right Grant
- 2016-07-11 JP JP2018520002A patent/JP6603802B2/ja active Active
- 2016-07-11 BR BR112018000206A patent/BR112018000206A2/pt not_active Application Discontinuation
- 2016-07-11 EP EP16820580.5A patent/EP3320521B1/en active Active
- 2016-07-11 ES ES16820580T patent/ES2781876T3/es active Active
- 2016-07-11 CA CA2991246A patent/CA2991246C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180143197A1 (en) | 2018-05-24 |
| ES2781876T3 (es) | 2020-09-08 |
| US10254284B2 (en) | 2019-04-09 |
| CA2991246C (en) | 2020-02-25 |
| EP3320521B1 (en) | 2020-03-25 |
| KR20180031702A (ko) | 2018-03-28 |
| WO2017004684A1 (en) | 2017-01-12 |
| EP3320521A4 (en) | 2019-01-23 |
| KR102046265B1 (ko) | 2019-11-18 |
| JP6603802B2 (ja) | 2019-11-06 |
| JP2018529975A (ja) | 2018-10-11 |
| EP3320521A1 (en) | 2018-05-16 |
| CN108027982A (zh) | 2018-05-11 |
| MX2018000104A (es) | 2018-06-20 |
| CA2991246A1 (en) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018000206A2 (pt) | indicador terapêutico atômico | |
| Akino et al. | Evaluation of superficial dosimetry between treatment planning system and measurement for several breast cancer treatment techniques | |
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| Sabater et al. | Dose accumulation during vaginal cuff brachytherapy based on rigid/deformable registration vs. single plan addition | |
| Fontenot et al. | Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy | |
| EP4282405A3 (en) | Detection of cancer biomarkers using nanoparticles | |
| Cho et al. | Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy | |
| ATE401630T1 (de) | Volumenmessungen in dreidimensionalen datensätzen | |
| JP2018509934A5 (pt) | ||
| MX2020002553A (es) | Metodos de diagnostico y terapeuticos para el cancer. | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| Solin | Counterview: pre-operative breast MRI (magnetic resonance imaging) is not recommended for all patients with newly diagnosed breast cancer | |
| Figueiredo et al. | Influence analysis of thermophysical properties on temperature profiles on the breast skin surface | |
| ES2625761A1 (es) | Método para la automatización en la calibración dosimétrica, reconstrucción y verificación de tratamientos complejos de radioterapia integrada en un entorno y sistema para la puesta en práctica del mismo | |
| EA201490946A1 (ru) | Способ количественной оценки лечения рака | |
| US10099067B2 (en) | Radiation therapy dose calculation | |
| SG11201900972UA (en) | Health-level measuring method, health-level determining apparatus, and hair-health examination system | |
| Fiandra et al. | Impact of the observers' experience on daily prostate localization accuracy in ultrasound‐based IGRT with the Clarity platform | |
| BR112015012548A2 (pt) | método | |
| JOP20190067A1 (ar) | طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري | |
| Delaby et al. | CyberKnife® M6™: Peripheral dose evaluation for brain treatments | |
| Wang et al. | TACC3 as an independent prognostic marker for solid tumors: a systematic review and meta-analysis | |
| Tuğral et al. | The effect of adjuvant radiotherapy on skin biophysical properties in patients with breast cancer at risk for breast lymphedema: A prospective study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |